Zeitschrift fur Rheumatologie最新文献

Muscle sonography is used in rheumatology, neurology, geriatrics, sports medicine and orthopedics. Muscular atrophy with fatty and connective tissue degeneration can be visualized and must be interpreted in conjunction with the sonographic findings of the supplying nerves. Sonography is becoming increasingly more important for the early diagnosis of sarcopenia in rheumatology, geriatrics and osteology. Even if its significance has not yet been conclusively clarified, many publications confirm the high reliability of the method. Sonography can ideally be used in addition to magnetic resonance imaging (MRI) in the diagnostics of myositis as it can speed up the diagnosis, muscle groups that were not imaged by MRI can also be assessed sonographically and all muscle groups can be examined during the course of the procedure. Sonography also helps to make a quick and uncomplicated diagnosis of many sports injuries in addition to MRI and is therefore the basis for a targeted therapeutic approach.

Objective: An observational study was conducted to determine whether semiquantitative scoring of ultrasound signs of gout predicted flare over 12 months.

Methods: Gout patients were enrolled consecutively in this 12-month prospective observational single-center study. Ultrasound evaluation and clinical assessment were performed at baseline. All patients were examined bilaterally evaluating 14 joints (knee, ankle, metatarsophalangeal joints 1-5) and 10 tendons (posterior tibial, quadriceps, peroneus longus and brevis scored as one, patellar, and Achilles tendons). The following ultrasound features were examined and semiquantitative scoring was performed: DC sign, aggregates, tophi, bone erosion, synovial hypertrophy, PD activity, and tenosynovitis. Patients were divided into two groups, one with flares during the follow-up period and the other without flares.

Results: A total of 119 participants completed the study; 61 (51.3%) participants experienced at least one flare over 12 months, with a median of 2.0 flares. The ultrasound findings indicative of DC sign, aggregate, tophi, bone erosion, and PD activity at baseline were significantly correlated with the development of gout flares over 12 months. Logistic regression analysis suggested that DC sign score (OR: 2.41, 95% CI: 0.92-4.37; P = 0.02), tophi score (OR: 1.87, 95% CI: 0.65-2.28; P = 0.04), and PD activity score (OR: 1.93, 95% CI: 0.58-3.26; P = 0.03) were independent predictors of flare. ROC curve analysis to assess ultrasound semiquantitative scoring has good sensitivity and specificity for the prediction of gout flares.

Conclusion: Ultrasound semiquantitative scoring can predict the risk of flare, and ultrasound findings indicative of DC sign, tophi, and PD activity are independent predictors of gout flares over 12 months.

Background: Synovial chondromatosis, or osteochondromatosis, is a rare benign disorder that occurs in joints, tendon sheaths, or bursae, characterized by cartilage proliferations of varying sizes and shapes, often with ossifications. In this study the prevalence, sensitivity, gender predominance, differential diagnoses, and primary localization of synovial chondromatosis are analyzed within the Histopathological Arthritis Registry of the German Society for Orthopedic Rheumatology.

Methods: All cases of patients diagnosed with "synovial chondromatosis" from the Histopathological Arthritis Registry of the German Society for Orthopedic Rheumatology were retrospectively examined, covering the period from 1 January 2018, to 31 December 2022.

Results: Between 1 January 2018, and 31 December 2022, there were 14 cases of synovial chondromatosis out of a total of 13,222 cases in the Histopathological Arthritis Register of the German Society for Orthopedic Rheumatology. The available data include primary localization, and age and gender of the patients. Among the 13,222 cases in the Histopathological Arthritis Register of the German Society for Orthopedic Rheumatology, 14 were histopathologically confirmed as synovial chondromatosis. This resulted in a prevalence of 0.1% or 1.13 per 1,000 cases. The correct clinical presumptive diagnosis was made in 5 cases, yielding a sensitivity of 35.7%, 95% confidence interval (CI) 12.8% to 64.9%.

Discussion: Differential diagnoses for this condition include pigmented villonodular synovitis, tenosynovial giant cell tumor, and chondrosarcoma. Synovial chondromatosis frequently occurs in large joints such as the knee, hip, and the temporomandibular joint. A peak incidence is described in the fifth decade of life. However, the disorder can also occur in children. For the first time, the study was able to provide data for Germany based on a large sample. Additionally, initial statements regarding the prevalence and sensitivity of synovial chondromatosis could be made. The aim of this work is to raise awareness of this very rare disease to enable faster and more efficient diagnosis. The study also highlights the importance of histopathology in the diagnosis of synovial chondromatosis.

A German expert committee recommends defining fast-track clinics (FTC) for the acute diagnosis of giant cell arteritis (GCA) as follows: easy and prompt reachability at least on weekdays, scheduling appointments ideally within 24 h, examination by a specialist with GCA expertise, ≥ 2 experts per FTC, ≥ 50 patients with suspected GCA per year, sonologists with ≥ 300 (≥ 50) temporal and axillary artery examinations, adherence to standard operating procedures, availability of an ≥ 18 (≥ 15) MHz and a lower frequency linear ultrasound probe, and collaboration with partners for neurology and ophthalmology consultations, magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT, possibly CT), and for temporal artery biopsy.

Objective: The aim of this study was to assess the relationships between urate-lowering therapy (ULT) and both all-cause and cardiovascular disease (CVD)-specific mortality in patients diagnosed with gout or hyperuricemia.

Methods: The PubMed, Embase, and Cochrane databases were thoroughly searched to gather literature on overall and/or CVD-specific hazard ratios (HRs) of patients with gout or hyperuricemia. A meta-analysis was conducted to evaluate the mortality risks of UTL users in gout or hyperuricemia populations.

Results: This meta-analysis included 11 comparative studies encompassing 38,396 ULT users and 47,530 controls for evaluating all-cause mortality in gout or hyperuricemia. ULT treatment in patients with gout or hyperuricemia led to a significantly lower risk of all-cause mortality compared to patients not receiving ULT (HR = 0.783, 95% confidence interval [CI] = 0.702-0.874; p < 0.001). Both ULT and allopurinol were associated with decreased all-cause mortality rates (ULT HR = 0.651, 95% CI = 0.520-0.816; p < 0.001; allopurinol HR = 0.836, 95% CI = 0.731-0.957; p = 0.009). ULT initiation significantly reduced CVD-specific mortality in hyperuricemia patients, although the same was not observed in gout patients (HR for hyperuricemia = 0.872, 95% CI = 0.796-0.955; p = 0.003; HR for gout = 0.676, 95% CI = 0.296-1.544; p = 0.353).

Conclusion: This meta-analysis indicates that ULT substantially reduces all-cause mortality in patients with gout or hyperuricemia, although allopurinol does not significantly affect CVD-specific mortality. These results underscore the potential of ULT for enhancing survival rates in special patient populations.

Large vessel vasculitis, such as giant cell arteritis (GCA) and Takayasu arteritis (TAK) are primarily manifested on large and medium-sized arteries. While GCA mainly affects older people after the 6th decade of life onwards, TAK mainly affects young women under the age of 40 years. Glucocorticoids (GC) are still the standard treatment for both diseases. Refractory courses and relapses in particular often lead to long-term treatment with high cumulative doses of GC, which can lead to increased morbidity and mortality. To date, only the interleukin 6 (IL-6) receptor blocker tocilizumab has been approved for the treatment of GCA. The data on methotrexate and other conventional immunosuppressants are incomplete and in some cases contradictory. The early use of steroid-sparing immunosuppressants is recommended for TAK, although the number of randomized placebo-controlled trials is limited and no steroid-sparing treatment has yet been approved for TAK. For both diseases there is still a great need for modern and safe steroid-sparing treatment that effectively treats vasculitis, prevents damage and enables adequate disease monitoring. This article provides an overview of the current study situation and possible future treatment options for GCA and TAK.

Background: Interdisciplinary medical treatment is required to care for patients with complex autoimmune diseases. Although there are an increasing number of interdisciplinary centers for autoimmune diseases in Germany, they are not yet available throughout the country and the focuses and interdisciplinary structures are not organized according to a generally agreed standard. Furthermore, they are not regularly reflected in the general care structure.

The aim of the work: To analyze the care structure using as an example an established center and a clinical case to demonstrate the usefulness of in-house standardized procedures.

Material and methods: In order to determine the status quo regarding interdisciplinary centers for autoimmune diseases in Germany, a university hospital is exemplarily presented for a structural analysis and a case presentation from another center to demonstrate the importance of an interdisciplinary patient care.

Results: At the selected center for autoimmune diseases of the university hospital, patients with autoimmune diseases receive interdisciplinary care from experts from various disciplines. The structures are anchored in an organizational chart. The case report demonstrates a standardized diagnostic and therapeutic pathway (standardized operating procedures, SOP) in a patient with systemic sclerosis and lung involvement.

Discussion: The article discusses which measures are necessary across disciplines for comprehensive diagnostics and treatment of certain autoimmune diseases, which challenges arise during implementation and which advantages can arise compared to guidelines because, among other things, they can be immediately adapted. The establishment of a national consensus for the structure, necessary settings and implementation into patient care within an interdisciplinary center for autoimmune diseases is desirable.

Large vessel vasculitis, including giant cell arteritis (GCA) and Takayasu arteritis (TAK), are autoimmune diseases primarily affecting the aorta and its branches. GCA is the most common primary vasculitis. Inflammatory changes in the vessel walls can cause serious complications such as amaurosis, stroke, and aortic dissection and rupture. Imaging techniques have become an integral part for the diagnosis and monitoring of large vessel vasculitis, allowing for effective disease monitoring. GCA and TAK exhibit similar patterns of vascular distribution. However, the temporal arteries are never involved in TAK, and axillary arteritis occurs more frequently in GCA. In most centers, ultrasound of the temporal and axillary arteries has replaced temporal artery biopsy as the primary diagnostic tool for GCA. In addition to ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), and [¹⁸F]-FDG (fluorodeoxyglucose) positron emission tomography-computed tomography (PET) are important, particularly for visualizing the aorta. Moreover, PET-CT is now also capable of assessing the temporal arteries, although it is not yet widely available. In polymyalgia rheumatica (PMR), ultrasound of the shoulder and hip regions is part of the ACR/EULAR classification criteria. MRI allows detailed visualization of additional inflammatory extraarticular manifestations, showing characteristic inflammatory lesions in entheses, tendons, and ligaments. [¹⁸F]-FDG-PET-CT also enables the visualization of musculoskeletal inflammation, especially in the shoulder and hip regions, as well as paravertebral areas. Ultrasound can detect subclinical GCA in up to 23% of patients with PMR, which should be treated like GCA. Technological innovations such as new radiotracers and improved MRI imaging could further enhance the diagnosis and monitoring of large vessel vasculitis and PMR, thus playing a crucial role in improving the prognosis through faster initiation of therapy.